# Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

> **NCT03371251** · PHASE1,PHASE2 · COMPLETED · sponsor: **Boston Pharmaceuticals** · enrollment: 143 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** BOS161721
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03371251
- **Lead sponsor:** Boston Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-10
- **Primary completion:** 2020-11-26
- **Final completion:** 2020-11-26
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03371251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03371251, "Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03371251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*